Phase II trials
|Compound||Type of drug||Tumour type|
|Xentuzumab (BI 836845)†||IGF ligand monoclonal antibody||Metastatic breast cancer (oestrogen-receptor positive)|
|BI 1361849†||Immunotherapeutic cancer mRNA vaccine||Non-small cell lung cancer|
|BI 836826†||CD37 monoclonal antibody||
Chronic lymphocytic leukaemia
Non-Hodgkin lymphoma (relapsed or refractory)
†This is an investigational compound and has not yet been fully approved. Its safety and efficacy has not yet been fully established.
IGF, Insulin-like growth factor; mRNA, messenger ribonucleic acid.
Last updated August 2016.